Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.39 -0.4%	$1.75	$0.87 ▼ $6.37	$241.89M	0.86	843,122 shs	712,674 shs
ANNX Annexon	$2.12 +0.5%	$2.45	$1.28 ▼ $7.85	$232.97M	1.3	1.55 million shs	843,480 shs
INMB INmune Bio	$2.09 +2.0%	$3.04	$1.89 ▼ $11.64	$55.55M	0.97	1.54 million shs	600,921 shs
TKNO Alpha Teknova	$4.31 -3.1%	$4.77	$4.00 ▼ $10.37	$230.63M	0.32	359,473 shs	272,823 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+1.69%	+9.09%	+36.36%	+69.01%	-54.63%
ANNX Annexon	-1.86%	-1.40%	-15.26%	-3.21%	-65.12%
INMB INmune Bio	-5.09%	-13.14%	-29.55%	-72.15%	-70.96%
TKNO Alpha Teknova	-2.63%	0.00%	-13.42%	-24.70%	-3.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	4.1282 of 5 stars	3.1	2.0	4.5	4.1	2.5	0.0
ANNX Annexon	2.6285 of 5 stars	3.4	3.0	0.0	2.9	2.5	0.0
INMB INmune Bio	2.0031 of 5 stars	3.3	2.0	0.0	1.7	1.7	0.6
TKNO Alpha Teknova	2.4142 of 5 stars	3.8	1.0	0.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	70.42% Upside
ANNX Annexon	2.75	Moderate Buy	$12.50	482.75% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	778.28% Upside
TKNO Alpha Teknova	3.50	Strong Buy	$10.00	134.74% Upside

Current Analyst Ratings Breakdown

Latest INMB, ALEC, TKNO, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	ANNX Annexon	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/15/2025	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
7/22/2025	TKNO Alpha Teknova	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.46	N/A	N/A	$0.70 per share	3.49
ANNX Annexon	N/A	N/A	N/A	N/A	$1.81 per share	N/A
INMB INmune Bio	$10K	5,568.51	N/A	N/A	$1.09 per share	1.92
TKNO Alpha Teknova	$37.74M	6.04	N/A	N/A	$1.42 per share	3.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	11/5/2025 (Estimated)
ANNX Annexon	-$138.20M	-$1.29	N/A	N/A	N/A	N/A	-70.04%	-57.67%	11/13/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
TKNO Alpha Teknova	-$26.75M	-$0.42	N/A	N/A	N/A	-55.24%	-26.51%	-18.40%	11/6/2025 (Estimated)

Latest INMB, ALEC, TKNO, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ANNX Annexon	-$0.36	-$0.34	+$0.02	-$0.34	N/A	N/A
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
8/7/2025	Q2 2025	TKNO Alpha Teknova	-$0.1004	-$0.07	+$0.0304	-$0.07	$9.90 million	$10.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
TKNO Alpha Teknova	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
ANNX Annexon	N/A	5.67	5.67
INMB INmune Bio	N/A	4.20	4.20
TKNO Alpha Teknova	0.17	5.87	4.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
ANNX Annexon	N/A
INMB INmune Bio	12.72%
TKNO Alpha Teknova	13.81%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
ANNX Annexon	11.87%
INMB INmune Bio	35.70%
TKNO Alpha Teknova	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
ANNX Annexon	60	109.89 million	96.84 million	Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
TKNO Alpha Teknova	240	53.51 million	46.83 million	Not Optionable

INMB, ALEC, TKNO, and ANNX Headlines

Recent News About These Companies

Alpha Teknova (NASDAQ:TKNO) Announces Earnings Results

August 11, 2025 | marketbeat.com

Alpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call Transcript

August 9, 2025 | seekingalpha.com

Alpha Teknova (TKNO) Q2 Revenue Jumps 7%

August 8, 2025 | aol.comA

CenterBook Partners LP Takes Position in Alpha Teknova, Inc. (NASDAQ:TKNO)

August 8, 2025 | marketbeat.com

Teknova Reports Second Quarter 2025 Financial Results

August 7, 2025 | globenewswire.com

Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025

July 24, 2025 | globenewswire.com

Pleasing Signs As A Number Of Insiders Buy Alpha Teknova Stock

July 9, 2025 | finance.yahoo.com

Martha J. Demski Sells 8,000 Shares of Alpha Teknova, Inc. (NASDAQ:TKNO) Stock

July 2, 2025 | insidertrades.com

Alpha Teknova, Inc. (TKNO) Income Statement - Yahoo Finance

June 28, 2025 | ca.finance.yahoo.com

Alpha Teknova, Inc. (NASDAQ:TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Alpha Teknova, Inc. (TKNO) Q1 2025 Earnings Call Transcript

May 10, 2025 | seekingalpha.com

Teknova Reports First Quarter 2025 Financial Results

May 8, 2025 | globenewswire.com

Alpha Teknova (TKNO) Traded Lower on Increased Uncertainty

April 30, 2025 | msn.com

Alpha Teknova, Inc. to Report First Quarter Financial Results on May 8, 2025

April 24, 2025 | quiverquant.comQ

Teknova to Report First Quarter 2025 Financial Results on May 8, 2025

April 24, 2025 | globenewswire.com

Alpha Teknova, Pluristyx launch proprietary PluriFreeze cryopreservation system

March 20, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | markets.businessinsider.com

Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

March 19, 2025 | globenewswire.com

Teknova, Pluristyx announce collaboration over next-generation cell therapies

March 11, 2025 | markets.businessinsider.com

Teknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell Therapies

March 11, 2025 | globenewswire.com

Earnings Update: Here's Why Analysts Just Lifted Their Alpha Teknova, Inc. (NASDAQ:TKNO) Price Target To US$10.67

March 8, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, ALEC, TKNO, and ANNX Company Descriptions

Alector NASDAQ:ALEC

$2.39 -0.01 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$2.39 0.00 (0.00%)

As of 05:30 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Annexon NASDAQ:ANNX

$2.12 +0.01 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.24%)

As of 04:56 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

INmune Bio NASDAQ:INMB

$2.09 +0.04 (+1.95%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 +0.02 (+0.72%)

As of 05:36 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Alpha Teknova NASDAQ:TKNO

$4.31 -0.14 (-3.15%)

Closing price 04:00 PM Eastern

Extended Trading

$4.31 0.00 (0.00%)

As of 04:11 PM Eastern

Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time